Abstract-Nonadherence to antihypertensive medications is known to be a major health problem. Novel biochemical analyses using liquid chromatography-tandem mass spectrometry are becoming accepted as a clinically useful objective measure to manage (non)adherence in Hypertension Clinics. Discussion of results from such analyses with patients can significantly improve adherence and blood pressure control. Our objective was to model the cost-effectiveness of performing liquid chromatography-tandem mass spectrometry-based analyses in improving adherence in patients with hypertension. Lifetime cost-utility was assessed from a UK healthcare payer perspective, using a Markov model. Efficacy was based on study findings of lowering blood pressure because of improved adherence to drug treatment. Cost and utilities were derived from literature. The base case cohort consisted of males aged 65 years. Subgroup analyses included varying population sex and age and a subgroup of patients with apparent resistant hypertension. Additionally, univariate and probabilistic sensitivity analyses were performed. Our findings are reported after the Consolidated Health Economic Evaluation Reporting Standards checklist. Per patient, screening resulted in 0.020 incremental quality-adjusted life-years and a negative incremental cost of £495, suggesting the intervention to be dominant compared with care as usual. Targeting younger patients or patients with apparent resistant hypertension would further improve these outcomes. Modeling suggested that screening prevented 518 myocardial infarctions and 305 stroke events in a cohort of 10 000 male hypertensive patients. Using liquid chromatography-tandem mass spectrometry-based biochemical analyses to improve adherence in hypertensive patients is likely to be an effective and cost-saving strategy, especially in patients with apparent resistant hypertension.
H ypertension is the leading cause of global disease burden and the major risk factor for mortality and cardiovascular diseases (CVD), such as angina, myocardial infarction (MI), and stroke. 1 From 2000 to 2010, the prevalence of hypertension has increased from 26.4% in men and 25.1% in women to 31.9% and 30.1%, respectively. All in all, over a billion patients suffer from the condition. 2, 3 The latest data from Euroaspire IV shows that blood pressure (BP) is optimally controlled in only half of the population. 4 Nonadherence to pharmacological therapies is a crucial reason for such poor control of BP. 5 Nonadherence in routine clinical practice has been difficult to identify as previous methods were unreliable, tedious, and not practical to use in busy clinics. 6 We and others [7] [8] [9] [10] [11] [12] [13] [14] have developed a robust, objective clinically useful method to detect antihypertensive drugs in urine or blood using liquid chromatography-tandem mass spectrometry (LC-MS/ MS). This is now becoming accepted as the standard technique to assess for nonadherence to antihypertensive medications. 15 A recent study using this technique has shown that nonadherence rates are around 30% to 40% in patients attending hypertension clinics in a large cohort of around 1350 patients from 2 European countries. 16 Furthermore, urine analysis and subsequent discussion of the results with the patient is associated with improved adherence to prescribed antihypertensive medications, resulting in improvements in BP control with average systolic BP (SBP) reductions of around 20 mm Hg. 17 
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The test is increasingly being used in routine clinical practice, however, the cost-effectiveness of implementing this technology in routine clinical practice is not known. The aim of this study was to determine the cost-effectiveness of LC-MS/ MS-based urine analysis added to current practice among patients with hypertension in the United Kingdom (UK).
Methods
Data used in this study is available from the referenced literature.
Overview
To assess the cost-effectiveness of LC-MS/MS-based urine analysis as compared with current practice, a Markov model was used. The model used in this study was an adaptation of an existing model developed by the School of Health and Related Research of the University of Sheffield. 18 Based on previous research, SBP was expected to decrease by 19.5 mm Hg. 17 As per guidelines for appraisal by the National Institute of Health and Care Excellence, the findings were expressed in terms of costs, quality-adjusted life-years (QALYs), and incremental costs per QALY, over a lifetime horizon, and from a health care payer perspective. Both costs and QALYs were discounted at a discount rate of 3.5% per annum. 19 To provide a comprehensive and transparent overview of the economic evaluation performed in this article, the Consolidated Health Economic Evaluation Reporting Standards statement was used as guidance. 20 The checklist is found in the online-only Data Supplement as Table S2 in the online-only Data Supplement.
Model Construction
The model is shown in Figure 1 . A cohort of 10 000 hypertensive patients progresses through the model in annual cycles, up to the age of 100 years, which was assumed to sufficiently reflect the entire lifetime of the patients. As the cohort ages, the probability of cardiovascular events and death increases.
A total of 12 health states were included in the model, 3 of which represent different forms of mortality. Patients enter the model in the event-free state, where patients are treated for hypertension but have not yet experienced a cardiovascular event. They may either remain in this health state or experience a primary major adverse cardiovascular event, including stable angina, unstable angina, MI, or a stroke or a fatal event and move to the appropriate health state. The health states following nonfatal events are acute health states (the 4 health states in the gray box in Figure 1 ), in which patients reside for 1 cycle. The following year, patients will then either move to a chronic health state if they experience no other CVD events or move to another acute health state. These chronic health states are modeled to be associated with a higher quality of life and lower costs compared with their respective acute states because the patients had undergone treatment in the acute phase of their disease. Patients in chronic CVD event states can move the same way as patients in the acute health states.
Patients can remain in the same health state for multiple cycles except for the acute coronary artery disease event states of stable angina and unstable angina, as patients in these health states are regarded as having been diagnosed with angina and are subsequently treated. Finally, all patients faced an all-cause-mortality risk every year, which was derived from the life tables for the UK for the years 2013 to 2015. 21 The reported mortality rates were subsequently converted to yearly probabilities.
Patient Characteristics
The target population consisted of a hypothetical cohort of 10 000 patients with treated hypertension (an office SBP of at least 140 mm Hg) but without history of CVD. The cohort in the base case analysis consisted of male patients with a starting age of 65, as this was assumed to adequately reflect the average hypertension patient.
Comparator
The LC-MS/MS-based urine analysis was introduced in patients with hypertension in addition to current practice. The comparative strategy consisted of current practice, that is, treating patients with antihypertensive drugs, in the absence of screening. Urine samples were collected at the general practitioner, and subsequently, the results were discussed with the patient during a later appointment. This screening strategy was repeated yearly. A detailed account on the methodology used for the LC-MS/MS-based analysis has been described previously described. 
Transition Probabilities
The risk for CVD in hypertensive patients was based on data from several studies. 18, [22] [23] [24] From these studies, yearly probabilities for developing major adverse cardiovascular event were derived. For the screening strategy, the reduction in CVD risk as compared with current practice was modeled by using relative risks (RRs) to transform the transitions from event-free to acute health states. These RRs were derived from Lewington et al, 25 reflecting the impact of a 20 mm Hg reduction of a patient's SBP on CVD as shown in our previous data from a UK cohort who underwent adherence testing using urine LC-MS/MS and were subsequently followed up. 17 Additionally, the effect of lower or higher SBP reductions was modeled. For example, for an SBP reduction of 19.5 mm Hg, the corresponding RR was calculated by raising the reported RR to the power 19.5/20. The RRs for ages 30 to 39 were not present in the meta-analysis, and these values were estimated assuming a linear extrapolation (Table 1 ). In the subgroup analysis for patients with apparent resistant hypertension, defined as uncontrolled hypertension, despite a 3-drug regiment, including a diuretic, 27 additional RRs were used. 26 The transition probabilities were multiplied with the appropriate RR because patients with resistant hypertension were found to have a higher risk for CVD as compared with nonresistant hypertensive patients.
Healthcare Costs
The cost-effectiveness analysis used a healthcare payer perspective in the UK, that is, the National Health Service perspective. Costs were derived from multiple sources, mostly from previous cost-effectiveness studies with a National Health Service perspective, [28] [29] [30] and are shown in Table 2 . Youman et al 30 reported the costs for an acute event of stroke separated according to severity: mild, moderate, and severe. However, because this study does not distinguish between severities of stroke, a weighted mean was calculated using the distribution of severities also found in Youman et al. 30 All costs are set to 2015/2016 prices in UK pounds. 33 To account for the uncertainty around the cost estimates, an SE was used, set to 25% of the mean value.
Utilities
In this analysis, the relationship between age and baseline utility was modeled using EuroQol 5 Dimensions (EQ-5D) values from Kind et al. 31 The utilities associated with the acute event states for stable angina, unstable angina, and MI were derived from Lovibond et al, 28 while the values for their respective chronic health states were adopted from other studies. 18, 34 Utilities for the acute and chronic stroke health states were based on quality of life estimates from the meta-analysis by Tengs and Lin. 32 This meta-analysis reported utilities for mild, moderate, and severe stroke at 0.87, 0.68, and 0.52, respectively. As with the stroke costs, our study did not distinguish between severities of stroke, and, therefore, a weighted mean was calculated, using the distribution of severities found in Youman et al. 30 The weighted mean for both acute and chronic stroke states was calculated as 0.63. All utility values used are shown in Table 2 . To account for uncertainty in utilities, the SE was set to 5% of the mean.
Analysis
The primary outcomes of this analysis included total costs, total lifeyears, total QALYs, and numbers of MI and stroke events over time. Costs and QALYs were used to estimate the incremental cost-effectiveness ratio (net costs per QALY gained). Total numbers of MI and stroke cases prevented by the urine screening methodology are also reported.
Subgroup Analysis
The base case analysis covered male hypertensive patients aged 65 years. To assess the outcomes for other cohorts, we performed subgroup analyses. Female cohorts were analyzed, as well as the starting age being varied from 35 to 85 years in 10-year increments. Furthermore, the impact of limiting the screening test to those with apparent resistant hypertension was tested.
Sensitivity Analyses
To evaluate the impact of uncertainty in model parameters, univariate and multivariate (probabilistic) sensitivity analyses were performed. All parameters, utilities, costs, RRs, and transition probabilities were varied over the ranges based on their respective SE. If no SE was available, the range was calculated from a certain percentage of the mean, as mentioned above. To draw random values for the parameters in sensitivity analyses, β, γ, and log-normal distributions were used. Utilities and transition probabilities were assigned β distributions, while γ distributions were used for costs and log-normal distributions for RRs.
In the univariate analysis, costs, utilities, transition probabilities, and RRs were separately varied to test their influence on the outcomes. Furthermore, a discount rate of 1.5% for both costs and effects was also tested, as well as variations on estimated SBP reductions with an upper and lower limit of 29 and 10 mm Hg, respectively.
In the probabilistic sensitivity analysis, the model was run for 1000 iterations, in which every parameter was randomly drawn from its respective distribution. To calculate the probability of LC-MS/ MS being cost-effective or even dominant, as compared with current practice, net monetary benefit was calculated, from which a cost-effectiveness acceptability curve was produced, which represents the probability of favorable cost-effectiveness for a range of willingness to pay per QALY thresholds.
Results

Base Case
In the base case cohort of males aged 65 years, the model showed that LC-MS/MS-based urine screening for hypertension was CHD indicates coronary heart disease; CVA, cerebrovascular accident; IHE, ischemic heart event; and RH, resistant hypertension.
*Assumption, no 95% CI from literature, set to 15% of the mean.
dominant, suggesting that this method of screening is likely to be both more effective and less costly, compared with current practice. Notably, the costs in the screening strategy were lower than in current practice (£69 357 versus £69 852). The modeled life expectancy was higher in the screening strategy (11.80 versus 11.78 life-years), and when adjusted for quality of life, patients obtained an incremental benefit of 0.020 QALYs (8.83 versus 8.81 QALYs) over current practice. Furthermore, the model predicted that the screening is likely to prevented 518 MI cases and 305 stroke cases over a lifetime horizon, be it fatal or nonfatal.
Subgroup and Scenario Analysis
Results for cohorts by sex and at ages 35 through to 85 years in 10-year increments are shown in Table 3 . In all subgroups, costs were saved and QALYs were gained as compared with care as usual, indicating dominance of LC-MS/MS testing. Furthermore, a subgroup consisting of patients with apparent resistant hypertension was explored. 27 Finally, the influence of other cohort parameters, such as estimated SBP reduction and the discount rate on outcomes was explored in a scenario analysis (Table S1) .
As was already apparent from the subgroup analyses, cost-effectiveness in older patients and women was less favorable as compared with the cohort of 65-year old males, whereas in younger patients it was more dominant. Targeting only those with apparent resistant hypertension would improve both cost savings and QALY gains. This is most probably because of worse adherence in this group, 16 which is likely to result in greater improvements in SBP. Logically, when the effect of the intervention on SBP would be different than assumed in the base case model, this would impact cost-effectiveness, where better effect would mean better cost-effectiveness and vice versa. Last, lowering the discount rate for both costs and health effects would increase the current value of future savings and QALY gains, and, therefore, this has a favorable effect on cost-effectiveness.
Univariate Sensitivity Analysis
The results of the univariate sensitivity analysis are shown in the tornado diagrams in Figure 2 . Changes in utilities naturally did not influence the incremental costs, and the screening remained dominant in all analyses.
Probabilistic Sensitivity Analysis
The probabilistic sensitivity analysis performed 1000 iterations of the model. The base case incremental cost-effectiveness scatter plot of LC-MS/MS-based urine screening versus standard of care is shown in Figure 3 . The screening strategy gained QALYs in 100% of iterations while being cost saving in 86.8% of iterations. Assuming a willingness to pay threshold of £20 000 per QALY, the screening test was cost-effective in 95.4% of iterations. Figure S1 shows the influence of the willingness to pay threshold on the cost-effectiveness of the LC-MS/MS-based urine screening test in the cost-effectiveness acceptability curve. It shows the screening test to be cost-effective with a probability of 86.8% with a willingness to pay threshold of £0 per QALY, and it reached 99.3% at £50 000 per QALY.
Discussion
This is the first study to model cost-effectiveness of an objective pharmacological adherence intervention in people with hypertension from a UK perspective. As in any model, results are based on assumptions that may not necessarily reflect clinical reality. Still, using the best available information, the study suggests that from the base case analysis, the screening strategy dominates over current practice, with cost savings of £495 per patient, averting 518 MIs and 305 stroke events and gaining 200 QALYs over the lifetime of the cohort of 10 000 males aged 65. To assess the influence of cohort characteristics, subgroup analyses were performed. About cohort age, a clear pattern was found in its influence on costs and effects. Performing LC-MS/MS-based urine screening in younger cohorts improved the cost savings and QALY gains while screening an older population is likely to have reduced cost savings and QALYs gained. This is because of the fact that screening at an earlier age improves the patients' SBP with reduced lifetime risk of cardiovascular events. This was supported in the probabilistic sensitivity analysis, which showed that increasing patient starting age decreases the likelihood of intervention being cost-effective. In the subgroup analysis with a female cohort, cost savings were reduced, while effects proportionally increased more. In patients with apparent resistant hypertension who underwent discussions on the basis of the urine analysis, there was an increase in the cost savings and QALY gains over the base case. The improved outcomes are a result of focusing treatment on patients with a higher probability of encountering a cardiovascular event, and the higher incidence of nonadherence in this cohort of 30% to 40%. 16 As expected, increasing the estimated SBP reduction resulted in more favorable results, as patients would be less susceptible to CVD.
A main strength of this model is the possibility for subgroup analyses, covering a wide range of possible patient ages, as well as the sex of the cohort and whether patients had apparent resistant hypertension. This model also has some limitations. First, because of a lack of hypertension-specific transition probabilities, papers reporting on the general population were used, which may underestimate the actual probabilities of hypertensive patients developing CVD. This means the cost-effectiveness may be more favorable than now reported. In addition, heart failure, end-stage renal disease, and transient ischemic attacks were not explicitly included in the model, as their impact might be slightly lower as compared with the impact of included complications. However, exclusion of these events implies an underestimation of possible cost savings and QALY gains from better BP control, reflecting a conservative approach towards cost-effectiveness. Furthermore, this study focused solely on clinical SBP measurements. International guidelines also recommend management and targets for diastolic BP. In addition, this analysis did not consider the costs savings in terms of decreased costs of referrals to select clinics and reduce cost of investigations or additional therapy, but, clearly, these would increase the cost savings and health gains of the intervention. Ideally, cost-effectiveness analysis is done using both data from randomized controlled trials next to observational data; yet, randomized controlled trials are currently ongoing. Finally, there were limitations about the estimated SBP reduction. As Gupta et al 17 mention in their limitations, bias may have been introduced from incomplete data, resulting in a more favorable SBP reduction and the inability to follow the presumable drop in sustained adherence after checkups. By administering the test yearly, adherence would be more likely to be sustained, at greater costs.
Our results are supported by a previous study by Chung et al, 35 where therapeutic drug monitoring for adherence was proven to have a potential cost-effective role. Other previous studies have also shown that interventions to improve adherence are potentially cost-effective. Chapman et al 36 performed a post hoc modeling study in combination with a systematic review on the cost-effectiveness of several strategies aimed at improving adherence of lipid-lowering and antihypertensive treatment and found an incremental cost-effectiveness ratio of £4451 ($4984) per QALY gained for self-monitoring, reminders, and educational materials as compared with no adherence intervention. Pharmacist/nurse management as compared with self-monitoring, reminders, and educational materials had an incremental cost-effectiveness ratio of £5678 ($6358) per QALY gained. Depending on the willingness to pay for a QALY, both these interventions can be considered cost-effective. More recently, Vegter et al 37 studied the cost-effectiveness of a pharmaceutical care intervention program in Dutch community pharmacies that improved patients' adherence to lipid-lowering therapy. They found both QALY gains and cost savings, as in the present study.
Although some uncertainties remain, such as the exact SBP reduction and the extent of sustained adherence, it is likely that screening for nonadherence to antihypertensive medications is cost-effective. The urine analysis would prove to be the most cost-effective in younger patients and patients with apparent resistant hypertension. Additionally, it would improve the number of MI and stroke cases prevented. However, from a public health perspective, it would still be beneficial to perform this intervention strategy in all patients with hypertension with dominance remaining over all groups and ages, albeit the efficiency of resource use would be slightly lower. In addition, a more widespread use of screening could decrease the costs of performing the test, thus improving cost-effectiveness.
Perspectives
Analyses with our Markov model demonstrate that screening for nonadherence in hypertensive patients to improve adherence to antihypertensive medications in addition to current practice is likely to be a dominant intervention in preventing CVD, with both cost savings and health gains in the base case. These cost savings and health gains were robust in scenario and sensitivity analyses, although not all uncertainties could be fully addressed. In future assessments, a wider range of CVD should be accounted for, as these are frequently found in practice as well. In addition, studies about sustained adherence and true SBP reduction would further improve the accuracy of health economic assessments. Finally, the addition of this screening test could also be assessed for other countries. 
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